Jan Philipp Bewersdorf

May 16, 2024 | onlinelibrary.wiley.com | Rebecca Bystrom |Jan Philipp Bewersdorf |Shai Shimony |Rory M. Shallis |Yiwen Liu |guillaume BERTON | +9 more

To the Editor: Intensive induction chemotherapy followed by consolidation therapy with additional chemotherapy and/or an allogeneic hematopoietic stem cell transplant (allo-SCT) is the standard of care for younger and fit patients with acute myeloid leukemia (AML).1 For older AML patients or those deemed unfit for intensive chemotherapy, the addition of the BCL2 inhibitor venetoclax to hypomethylating agents (HMA + VEN) has been shown to improve overall survival (OS) compared with HMA...

Feb 20, 2024 | nature.com | Shai Shimony |Jan Philipp Bewersdorf |Rory M. Shallis |Guido Marcucci |Daniel DeAngelo |Donna S. Neuberg | +1 more

AbstractMolecularly defined secondary acute myeloid leukemia is associated with a prior myeloid neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined secondary AML patients (n = 395) treated with daunorubicin and cytarabine (7 + 3, n = 167), liposomal daunorubicin and cytarabine (CPX-351, n = 66) or hypomethylating agents (HMA) + venetoclax (VEN) (n = 162). Median overall survival (OS) was comparable between treatment groups among patients aged >60 years.

Jul 28, 2023 | onclive.com | Jan Philipp Bewersdorf

Jan Bewersdorf, MD, hematology/oncology fellow, Memorial Sloan Kettering Cancer Center, discusses the design of an ongoing phase 1 (NCT05714072) investigating ruxolitinib (Jakafi) plus abemaciclib (Verzenio) in patients with primary or secondary myelofibrosis. This multicenter, dose-escalation trial aims to determine whether the addition of the CDK4/6 inhibitor abemaciclib to the JAK inhibitor ruxolitinib improves ruxolitinib efficacy in patients with myelofibrosis.